Row | STUDYID | DOMAIN | ETCD | ELEMENT | TESTRL | TEENRL | TEDUR |
---|
1 | EX2 | TE | SCRN | Screen | Informed consent | 2 weeks after start of Element | P14D |
2 | EX2 | TE | PUSL | PlaceboUsual | First dose of a treatment product administration in Product Exposure Epoch, where dose is placeboproduct is the usual tobacco product | 2 weeks after start of Element | P14D |
3 | EX2 | TE | 5TPA5 mg | TP A | First dose of a treatment product administration in Product Exposure Epoch, where dose is 5 mg drugtobacco product A | 2 weeks after start of Element | P14D |
4 | EX2 | TE | 10TPB10 mg | TP B | First dose of a treatment product administration in Product Exposure Epoch, where dose is 10 mg drugtobacco product B | 2 weeks after start of Element | P14D |
5 | EX2 | TE | REST | Rest | 48 hrs after After last dose of preceding treatment Product Exposure Epoch | 1 week after start of Element | P7D |
6 | EX2 | TE | FU | Follow-up | 48 hrs after After last dose of third treatment last preceding Product Exposure Epoch | 3 weeks after start of Element | P21D |